Novo Nordisk’s obesity drug Saxenda approved by FDA

24 December 2014
novo-nordisk-big

Continuing its rush of year-end drug approvals, the US Food and Drug Administration late yesterday approved Danish diabetes care giant Novo Nordisk’s (NOV: N) New Drug Application for Saxenda (liraglutide 3mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.

Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 30kg/m2 or greater (obesity) or who are overweight (BMI 27kg/m2) with at least one weight-related co-morbidity such as type 2 diabetes and cardiovascular disease. The active ingredient liraglutide is already marketed at a lower dosage for the treatment of diabetes as Victoza and has reached blockbuster status in that indication

"Many people with obesity suffer from co-morbidities. Saxenda has the potential to help some of these people achieve and maintain a clinically significant weight loss and improve their weight-related co-morbidities," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

Sales projections

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical